Bicycle Therapeutics establishes U.S. operations

Thursday, May 26, 2016

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptides (Bicycles) platform, has established U.S. operations with headquarters in Cambridge, Massachusetts and named Rosamond Deegan, MBA, as president and chief business officer. In this newly created role, Deegan will be responsible for leading Bicycle Therapeutics’ business development activities and establishing a U.S. team aligned with the Company’s focus on oncology clinical development.

[Read More]

Trevena receives FDA Breakthrough Therapy for Oliceridine in pain

Tuesday, February 23, 2016

Trevena, a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, has announced the FDA granted Breakthrough Therapy designation to the company’s lead product candidate, intravenous oliceridine (TRV130), for the management of moderate-to-severe acute pain. Following two successful phase II studies, oliceridine is now in phase III development. The ATHENA-1 safety and tolerability study is ongoing, with pivotal studies expected to begin in the second quarter of 2016.

[Read More]

Trevena, Forest Labs to develop TRV027 for acute heart failure

Thursday, May 9, 2013

Trevena, a clinical stage pharmaceutical company focused on G-protein coupled receptor (GPCR) biased ligands, and Forest Laboratories, a global pharmaceutical company, have entered into a collaborative licensing option agreement for the development of TRV027, an AT1R biased-ligand that recently completed phase IIa clinical trials. Trevena expects to commence a 500-patient multi-center phase IIb clinical trial in acute decompensated heart failure (ADHF) by year end.

[Read More]